



GlaxoSmithKline

FAX

To Group 1624

Company USPTO

Fax 703-872-9306

From Allyson K. Jacobs

Tel 919-483-9105 **Fax** 919-483-7988

E-mail aki27836@glaxowellcome.com

Date 26-Aug-2003 **Pages including cover** 22

Subject Serial No.: 10/071,358

 Filing Date: 2/8/02

Glaxo Wellcome Inc.
 PO Box 13398
 Five Moore Drive
 Research Triangle Park
 North Carolina 27709
 Tel: 919 483 2100
 www.gsk.com

Attached:

- Terminal Disclaimer + copy
- Amendment Transmittal
- Response
- Supplemental IDS + copy
- Supplemental PTO 1449
- Certificate of Transmission

FAX RECEIVED

AUG 27 2003

GROUP 1600

OFFICIAL

The information contained in these documents is confidential and may also be privileged and is intended for the exclusive use of the addressee designated above. If you are not the intended recipient or the employee or agent responsible to deliver it to the intended recipient, any disclosure, reproduction, distribution, or any other dissemination or use of this communication is strictly prohibited. If you have received this transmission in error please contact us immediately by telephone so that we can arrange for its return.

AMENDMENT TRANSMITTAL LETTER (Large Entity) Applicant(s): Carter et al.	Docket No. PG3416US2
---	--------------------------------

Serial No. 10/071,358	Filing Date 2/8/02	Examiner T. Truong	Group Art Unit 1624
--------------------------	-----------------------	-----------------------	------------------------

Invention: **HETEROCYCLIC COMPOUNDS**

TO THE COMMISSIONER FOR PATENTS:

Transmitted herewith is an amendment in the above-identified application.
The fee has been calculated and is transmitted as shown below.

CLAIMS AS AMENDED

	CLAIMS REMAINING AFTER AMENDMENT	HIGHEST # PREV. PAID FOR	NUMBER EXTRA CLAIMS PRESENT	RATE	ADDITIONAL FEE
TOTAL CLAIMS	27 -	36 =	0 x	\$18.00	\$0.00
INDEP. CLAIMS	3 -	3 =	0 x	\$84.00	\$0.00
Multiple Dependent Claims (check if applicable) <input type="checkbox"/>					\$0.00
TOTAL ADDITIONAL FEE FOR THIS AMENDMENT					\$0.00

- No additional fee is required for amendment.
- Please charge Deposit Account No. _____ in the amount of _____
- A check in the amount of _____ to cover the filing fee is enclosed.
- The Director is hereby authorized to charge payment of the following fees associated with this communication or credit any overpayment to Deposit Account No. **07-1392**
 - Any additional filing fees required under 37 C.F.R. 1.16.
 - Any patent application processing fees under 37 CFR 1.17.

John L. Lemanowicz
Signature

Dated: *August 26, 2003*

John L. Lemanowicz, Reg. 37,380
Attorney for Applicants
GlaxoSmithKline
Five Moore Drive, PO Box 13398
Research Triangle Park, NC 27709-3398

I certify that this document and fee is being deposited on _____ with the U.S. Postal Service as first class mail under 37 C.F.R. 1.8 and is addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.
<i>Signature of Person Mailing Correspondence</i>
Typed or Printed Name of Person Mailing Correspondence


cc:

CERTIFICATE OF TRANSMISSION BY FACSIMILE (37 CFR 1.8)	Docket No. PG3416US2
Applicant(s): Bountra et al.	

Serial No. 10/071,358	Filing Date 2/8/02	Examiner T. Truong	Group Art Unit 1624
---------------------------------	------------------------------	------------------------------	-------------------------------

Invention: **HETEROCYCLIC COMPOUNDS**

I hereby certify that this Amendment
(Identify type of correspondence)
 is being facsimile transmitted to the United States Patent and Trademark Office (Fax. No. 703-872-9306)
 on 8/26/03
(Date)

Allyson K. Jacobs
(Typed or Printed Name of Person Signing Certificate)

(Signature)

Note: Each paper must have its own certificate of mailing.

FAX RECEIVED
AUG 27 2003
GROUP 1600

OFFICIAL